Literature DB >> 28062403

Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer.

Carl Koschmann1,2, Felipe J Nunez2,3, Flor Mendez3, Jacqueline A Brosnan-Cashman4, Alan K Meeker4,5, Pedro R Lowenstein2,3, Maria G Castro6,3.   

Abstract

Genes encoding proteins that regulate chromatin structure and DNA modifications [i.e., chromatin regulatory factors (CRF)] and genes encoding histone proteins harbor recurrent mutations in most human cancers. These mutations lead to modifications in tumor chromatin and DNA structure and an altered epigenetic state that contribute to tumorigenesis. Mutated CRFs have now been identified in most types of cancer and are increasingly regarded as novel therapeutic targets. In this review, we discuss DNA alterations in CRFs and how these influence tumor chromatin structure and function, which in turn leads to tumorigenesis. We also discuss the clinical implications and review concepts of targeted treatments for these mutations. Continued research on CRF mutations will be critical for our future understanding of cancer biology and the development and implementation of novel cancer therapies. Cancer Res; 77(2); 227-33. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28062403      PMCID: PMC5243833          DOI: 10.1158/0008-5472.CAN-16-2301

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

Authors:  Alan H Shih; Yanwen Jiang; Cem Meydan; Kaitlyn Shank; Suveg Pandey; Laura Barreyro; Ileana Antony-Debre; Agnes Viale; Nicholas Socci; Yongming Sun; Alexander Robertson; Magali Cavatore; Elisa de Stanchina; Todd Hricik; Franck Rapaport; Brittany Woods; Chen Wei; Megan Hatlen; Muhamed Baljevic; Stephen D Nimer; Martin Tallman; Elisabeth Paietta; Luisa Cimmino; Iannis Aifantis; Ulrich Steidl; Chris Mason; Ari Melnick; Ross L Levine
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.

Authors:  David A Russler-Germain; David H Spencer; Margaret A Young; Tamara L Lamprecht; Christopher A Miller; Robert Fulton; Matthew R Meyer; Petra Erdmann-Gilmore; R Reid Townsend; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

3.  NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.

Authors:  Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Marta Pratcorona; Saman Abbas; Jenny E Kuipers; Janneke F van Galen; H Berna Beverloo; Edwin Sonneveld; Gert-Jan J L Kaspers; Jan Trka; Andre Baruchel; Martin Zimmermann; Ursula Creutzig; Dirk Reinhardt; Rob Pieters; Peter J M Valk; C Michel Zwaan
Journal:  Blood       Date:  2011-08-02       Impact factor: 22.113

4.  Molecular Coupling of Histone Crotonylation and Active Transcription by AF9 YEATS Domain.

Authors:  Yuanyuan Li; Benjamin R Sabari; Tatyana Panchenko; Hong Wen; Dan Zhao; Haipeng Guan; Liling Wan; He Huang; Zhanyun Tang; Yingming Zhao; Robert G Roeder; Xiaobing Shi; C David Allis; Haitao Li
Journal:  Mol Cell       Date:  2016-04-21       Impact factor: 17.970

Review 5.  Alternative lengthening of telomeres: models, mechanisms and implications.

Authors:  Anthony J Cesare; Roger R Reddel
Journal:  Nat Rev Genet       Date:  2010-03-30       Impact factor: 53.242

Review 6.  Epigenetic modifiers in normal and malignant hematopoiesis.

Authors:  Jessica N Haladyna; Taylor Yamauchi; Tobias Neff; Kathrin M Bernt
Journal:  Epigenomics       Date:  2015       Impact factor: 4.778

7.  Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF.

Authors:  Steven D P Moore; Steven R Herrick; Tan A Ince; Michael S Kleinman; Paola Dal Cin; Cynthia C Morton; Bradley J Quade
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

8.  NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.

Authors:  Gang G Wang; Ling Cai; Martina P Pasillas; Mark P Kamps
Journal:  Nat Cell Biol       Date:  2007-06-24       Impact factor: 28.824

9.  Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.

Authors:  Kasper D Rasmussen; Guangshuai Jia; Jens V Johansen; Marianne T Pedersen; Nicolas Rapin; Frederik O Bagger; Bo T Porse; Olivier A Bernard; Jesper Christensen; Kristian Helin
Journal:  Genes Dev       Date:  2015-04-17       Impact factor: 11.361

10.  Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.

Authors:  Huili Li; Katherine B Chiappinelli; Angela A Guzzetta; Hariharan Easwaran; Ray-Whay Chiu Yen; Rajita Vatapalli; Michael J Topper; Jianjun Luo; Roisin M Connolly; Nilofer S Azad; Vered Stearns; Drew M Pardoll; Nancy Davidson; Peter A Jones; Dennis J Slamon; Stephen B Baylin; Cynthia A Zahnow; Nita Ahuja
Journal:  Oncotarget       Date:  2014-02-15
View more
  22 in total

Review 1.  The critical role of histone lysine demethylase KDM2B in cancer.

Authors:  Meina Yan; Xinxin Yang; Hui Wang; Qixiang Shao
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  A chemoprobe tracks its target.

Authors:  Aseem Z Ansari
Journal:  J Biol Chem       Date:  2019-05-17       Impact factor: 5.157

3.  RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.

Authors:  William C Reinhold; Sudhir Varma; Margot Sunshine; Fathi Elloumi; Kwabena Ofori-Atta; Sunmin Lee; Jane B Trepel; Paul S Meltzer; James H Doroshow; Yves Pommier
Journal:  Cancer Res       Date:  2019-05-21       Impact factor: 12.701

4.  The mouse HP1 proteins are essential for preventing liver tumorigenesis.

Authors:  Nehmé Saksouk; Shefqet Hajdari; Yannick Perez; Marine Pratlong; Célia Barrachina; Céline Graber; Damien Grégoire; Aliki Zavoriti; Amélie Sarrazin; Nelly Pirot; Jean-Yohan Noël; Lakhdar Khellaf; Eric Fabbrizio; Eric Julien; Florence M Cammas
Journal:  Oncogene       Date:  2020-02-04       Impact factor: 9.867

5.  Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families.

Authors:  Jun Li; Hongyan Li; Igor Makunin; Bryony A Thompson; Kayoko Tao; Erin L Young; Jacqueline Lopez; Nicola J Camp; Sean V Tavtigian; Esther M John; Irene L Andrulis; Kum Kum Khanna; David Goldgar; Georgia Chenevix-Trench
Journal:  Breast Cancer Res Treat       Date:  2017-08-24       Impact factor: 4.872

6.  Histone Chaperone FACT and Curaxins: Effects on Genome Structure and Function.

Authors:  Han-Wen Chang; Ekaterina V Nizovtseva; Sergey V Razin; Tim Formosa; Katerina V Gurova; Vasily M Studitsky
Journal:  J Cancer Metastasis Treat       Date:  2019-11-29

7.  Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.

Authors:  Padma Kadiyala; Stephen V Carney; Jessica C Gauss; Maria B Garcia-Fabiani; Santiago Haase; Mahmoud S Alghamri; Felipe J Núñez; Yayuan Liu; Minzhi Yu; Ayman Taher; Fernando M Nunez; Dan Li; Marta B Edwards; Celina G Kleer; Henry Appelman; Yilun Sun; Lili Zhao; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

8.  ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.

Authors:  Tingting Qin; Brendan Mullan; Ramya Ravindran; Dana Messinger; Ruby Siada; Jessica R Cummings; Micah Harris; Ashwath Muruganand; Kalyani Pyaram; Zachary Miklja; Mary Reiber; Taylor Garcia; Dustin Tran; Carla Danussi; Jacqueline Brosnan-Cashman; Drew Pratt; Xinyi Zhao; Alnawaz Rehemtulla; Maureen A Sartor; Sriram Venneti; Alan K Meeker; Jason T Huse; Meredith A Morgan; Pedro R Lowenstein; Maria G Castro; Viveka Nand Yadav; Carl Koschmann
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.995

Review 9.  Epigenetic regulation in the tumorigenesis of MEN1-associated endocrine cell types.

Authors:  Sucharitha Iyer; Sunita K Agarwal
Journal:  J Mol Endocrinol       Date:  2018-04-03       Impact factor: 5.098

10.  A key HDAC6 dependency of ARID1A-mutated ovarian cancer.

Authors:  Lucia Altucci
Journal:  Nat Cell Biol       Date:  2017-07-28       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.